2021.3-至今    中科中山药物创新研究院，研究员、课题组长
2017.7-2020.11 美国密歇根大学安娜堡分校  博士后
2013.9-2017.6  复旦大学/药物化学  博士
2011.5-2013.9  葛兰素史克上海研发中心  药物化学研究员
2006.7-2011.4  上海睿智化学管理有限公司  高级有机合成研究员,组长
2004.9-2006.6  武汉大学/药物化学  硕士
1999.9-2003.7  武汉工程大学/药物制剂  本科

主要开展围绕泛素-蛋白酶体系统的药物化学研究，研究工作重点围绕肿瘤和神经退行性疾病等重大临床需求，设计和合成具有成药性的先导化合物，为创新药物研究开发奠定坚实基础。

1.在新药研发领域探索15年，熟练掌握从苗头化合物—先导化合物—临床前候选化合物的新药临床前研发的全流程，在药物化学的产业化研究方面也积累了十分丰富的经验；
2.研究主要聚焦于围绕肿瘤和神经退行性疾病；
3.曾在传统的不可成药靶点（undruggable targets）新药发现领域，采用变构抑制以及靶向蛋白降解等新的研发策略，开发小分子抑制剂/降解剂，取得了一系列重大科研成果；
4.在J. Med. Chem； Eur. J. Med. Chem等著名学术杂志上发表论文8篇；
5.申请美国发明专利5项，中国发明专利2项；
6.已有多个分子进入临床试验以及成为药物被FDA批准上市。

1.Mingliang Wang, Xixi Liu, Lu Zhou, Jidong Zhu* and Xun Sun*., Fluorination of 2-substituted benzo[b]furans with Selectfluor™., Org. Biomol. Chem., 2015, 13, 3190-3193

2.Mingliang Wang, Yimin Hu, Zhe Jiang, Hong C. Shen* and Xun Sun*., Divergent Copper-mediated dimerization and hydroxylation of benzamides involving C-H bond functionalization., Org. Biomol. Chem., 2016, 14, 4239-4246.

3.Mingliang Wang, Yanjia Fang, Shoulai Gu, Fangfang Chen, Zhengjiang Zhu, Xun Sun* and Jidong Zhu*., Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine  derivatives as potent and selective CYP17 inhibitors. Eur. J. Med. Chem., 2017, 132, 157-172.

4.Jingjing Xie#, Xiaojia Si#, Shoulai Gu, Mingliang Wang, Jian Shen, Haoyan Li, Jian Shen, Dan Li, Yanjia Fang, Cong Liu* and Jidong Zhu*., Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment. J. Med. Chem., 2017, 60, 10205-10219.

5.Mingliang Wang, Jilai Han, Xiaojia Si, Yimin Hu, Jidong Zhu* and Xun Sun*., Effective approach to ureas through organocatalyzed one-pot process. Tetrahedron Lett, 2018, 59, 1614-1618.

6.Jiantao Hu#, Biao Hu#, Mingliang Wang (co-first author)#, Fuming Xu#, Bukeyan Miao#, Chaoyie Yang, Mi Wang, Zhaomin Liu, Daniel Hayes, Krishnapriya Chinnaswamy, James Delproposto, Jeanne Stuckey, Shaomeng Wang*., Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). J. Med. Chem. , 2019, 62, 3, 1420-1443.

7.Mingliang Wang#, Jianfeng Lu#, Mi Wang, Chao-Yie Yang, Shaomeng Wang*., Discovery of SHP2-D26 as a First, Potent and Effective PROTAC Degrader of SHP2 Protein. J. Med. Chem. 2020, 63, 14, 7510-7528. Highlight as Feature Article and the first PTP family degrader.

8.Wang Shaomeng, Hu Jiantao, Hu Biao, Wang Mingliang, Xu Fuming, Miao Bukeyan. Estrogen Receptor Protein Degrader. WO2020142227A1.

9.Mahesh P. Paudyal#, Mingliang Wang (co-first author)#, Juha H. Siitonen, Yimin Hu，Muhammed Yousufuddin, Hong C. Shen*, John R. Falck*, László Kürti*., Intramolecular N-Me and N-H Amino etherification for the Synthesis of N-Unprotected 3-Amino-O-Heterocycles. Org. Biomol. Chem., 2021, 19, 557-560.